Lack of Bioequivalence between Different Formulations of Isosorbide Dinitrate and Hydralazine and the Fixed-Dose Combination of Isosorbide Dinitrate/HydralazineThe V-HeFT Paradox

被引：0

作者：

S. William Tam

Michael L. Sabolinski

Manuel Worcel

Milton Packer

Jay N. Cohn

机构：

[1] NitroMed,

[2] Inc.,undefined

[3] University of Texas Southwestern Medical Center,undefined

[4] University of Minnesota,undefined

来源：

Clinical Pharmacokinetics | 2007年 / 46卷

关键词：

Enalapril; Hydralazine; Bioequivalence Study; Isosorbide Dinitrate; Slow Acetylators;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：885 / 895

页数：10

共 46 条

[1] Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine - The V-HeFT paradox
Tam, S. William
Sabolinski, Michael L.
Worcel, Manuel
Packer, Milton
Cohn, Jay N.
CLINICAL PHARMACOKINETICS, 2007, 46 (10) : 885 - 895
[2] The V-HeFT paradox, identical doses of different formulations of isosorbide dinitrate and hydralazine are not bioequivalent and neither is bioequivalent to the fixed-dose combination of ISDN/hydralazine used in A-HeFT
Sabolinski, Michael L.
Packer, Milton
Tam, S. William
Worcel, Manuel
Cohn, Jay N.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 64A - 64A
[3] The benefits of the fixed-dose combination of isosorbide dinitrate and hydralazine in A-HeFT are not influenced by the absence or presence of diabetes
Miller, Alan
Yancy, Clyde W.
Sabofinski, Michael L.
Braman, Virginia M.
Worcel, Manuel
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 44A - 44A
[4] GENOMIC SCORE TO TARGET THERAPY WITH A FIXED DOSE COMBINATION OF HYDRALAZINE AND ISOSORBIDE DINITRATE
McNamara, Dennis M.
Feldman, Arthur
Yancy, Clyde
Taylor, Anne
Dries, Daniel
Hanley-Yanez, Karen
Halder, Indrani
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1353 - 1353
[5] Fixed-dose combination of isosorbide dinitrate and hydralazine improves quality of life in African Americans with heart failure: Results from A-HeFT
Carson, P
Ghali, J
Tam, SW
Worcel, M
JOURNAL OF CARDIAC FAILURE, 2005, 11 (06) : S150 - S150
[6] MORTALITY REDUCTION BY HYDRALAZINE-ISOSORBIDE DINITRATE THERAPY IN CONGESTIVE-HEART-FAILURE - THE V-HEFT STUDY
FRANCIS, GS
ARCHIBALD, DG
COHN, JN
CIRCULATION, 1986, 74 (04) : 508 - 508
[7] Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure
Angus, DC
Linde-Zwirble, WT
Tam, SW
Ghali, JK
Sabolinski, ML
Villagra, VG
Winkelmayer, WC
Worcel, M
CIRCULATION, 2005, 112 (24) : 3745 - 3753
[8] Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for black patients with heart failure
Tam, SW
Linde-Zwirble, WT
Worcel, M
Sabolinski, ML
Ghali, JK
Villagra, VG
Winkelmayer, WC
Angus, DC
CIRCULATION, 2005, 112 (17) : U705 - U705
[9] A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination
Cheng, Judy W. M.
CLINICAL THERAPEUTICS, 2006, 28 (05) : 666 - 678
[10] Results of the extension to A-HeFT [X-A-HeFT] support the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine (ISDN/HYD)
Yancy, Clyde W.
Ghali, Jalal K.
Braman, Virginia M.
Sabolinski, Michael L.
Worcel, Manuel
JOURNAL OF CARDIAC FAILURE, 2006, 12 (06) : S80 - S80

← 1 2 3 4 5 →